Navigation Links
Bioenergy Introduces Corvalen M(R) as a Natural Treatment Option for Fibromyalgia Symptoms
Date:5/27/2010

MINNEAPOLIS, May 27 /PRNewswire/ -- Fibromyalgia affects as many as one in 50 Americans, 90 percent of whom are women. Yet, despite its nearly epidemic status, patients still often rely on pharmaceutical options solely for treatment. That's why Bioenergy Life Science, Inc. (www.bioenergy.com) has introduced Corvalen M®, a natural treatment option for fibromyalgia symptoms.  

Fibromyalgia is a syndrome mainly associated with widespread muscular pains and fatigue. The exact causes of fibromyalgia are unknown; however, patients with fibromyalgia have been shown to have an alteration in muscle adenine nucleotide metabolism, leading to depleted energy reserves (1).  As an essential compound in increasing muscular energy pools and reducing metabolic strain in affected muscles, Corvalen M® has been shown to be effective against fibromyalgia symptoms (2).

Corvalen M® comprises D-Ribose, a simple, 5-carbon monosaccharide, or pentose sugar. D-Ribose helps accelerate the formation of adenosine triphosphate (ATP), the primary energy source of all living cells, which can lead to subsequent tissue recovery for fibromyalgia patients.

"Having had Chronic Fatigue Syndrome and Fibromyalgia back in 1975, I know what patients are going through," says Dr. Jacob Teitelbaum, M.D, one of the primary researchers of this study and the medical director of the Fibromyalgia and Fatigue Centers, Inc. "The good news is these illnesses have become very treatable!"

Teitelbaum conducted a multi-center study, in which 53 health practitioners enrolled 257 patients who had been diagnosed with fibromyalgia and/or chronic fatigue syndrome. Each patient was given D-Ribose (Corvalen) at a dose of five grams per day for three weeks. All patients were measured for changes in energy, sleep, cognitive function, pain and overall well-being.

Teitelbaum noted improvement in the first week of treatment. After three weeks, results showed statistically significant improvements in all five parameters, More than half of the study's patients showed improvement in energy (61 percent), followed by a 37 percent increase in overall well-being.  

Bioenergy Life Science, Inc. focuses its core technology on D-Ribose®, the primary ingredient in the Corvalen Medical Food family of products, which include Corvalen®, Corvalen M® and Corvalen® Chewable Wafers. D-Ribose® is the only ribose to receive GRAS (generally regarded as safe) affirmation, no questions letter from the Food and Drug Administration (FDA). D-Ribose® is found also in many energy drinks, bars and supplements.

For more information, contact Renee Cooper of Christie Communications at 805-969-3744 or rcooper@christiecomm.com.

(1)  Gebhart B, Jorgenson JA. Benefit of ribose in a patient with fibromyalgia. Pharmacotherapy. 2004 Nov;24(11):1646-8

(2)  Teitelbaum J, Johnson C, Cyr J. The Use of D-Ribose in Chronic Fatigue Syndrome and Fibromyalgia: A Pilot Study. The Journal of Alternative and Complementary Medicine. 2006 12(9):857-862


'/>"/>
SOURCE Bioenergy Life Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bersin & Associates Introduces New Talent Management Framework
2. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
3. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
4. Ethicon Endo-Surgery Introduces Two New Staplers for Open Surgical Procedures at ASCRS
5. Biosense Webster Introduces the THERMOCOOL(R) SF Irrigated Catheter in the European Union
6. Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access
7. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
8. Burton Medical Introduces the AIM-200(R) as a Versatile, Long-Lasting Light Source for Ambulatory Surgical Centers
9. Sikorsky Global Helicopters Introduces State-of-the-Art Emergency Medical Services Interior for S-76(R) Helicopter
10. Samplify Introduces New Compression Technology to Lower Costs for Mobile Operators Migrating to 4G
11. Bayer Diabetes Care Introduces DIDGET In the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):